For & Against
What's Next
The next three to six months are unusually catalyst-dense for a mid-cap medtech. The next earnings print lands in late May / early June 2026, inside an active Browning West cooperation window and with a strategic review of CooperSurgical underway. Q2 FY26 carries outsized weight because it is the first opportunity for CooperVision organic growth to print above 5% since the Q1 FY26 low of ~3% — the single number on which this entire debate turns.
The EPS line has beaten consensus for nine consecutive quarters — that is the management narrative. The revenue line has missed and been cut three times inside FY25 — that is the bear narrative. Q2 FY26 is where the two lines collide: a tenth EPS beat no longer moves the stock if CVI organic stays under 5%. The market is watching the organic print, not the EPS number.
For / Against / My View
The setup is a quality oligopoly at a thirteen-year low multiple, activists pressing for break-up, and a management team that has defended every EPS line but conceded ground on every growth line. Below are the three sharpest arguments on each side — lifted largely from Bull and Bear's drafts — followed by where they disagree on the same fact.
For
1. Cheapest multiple since 2013 on a 90/100 business
Cooper trades at 13.8x EV/EBITDA — the lowest since 2013 ex-2008 panic, 1.3 standard deviations below its 5-year mean of 20.5x and below its 20-year mean of 17.8x. A simple mean reversion to the 20-year median is the trade, and the Quality Score of 90/100 says this is not a value trap.
Numbers — "13.8x EV/EBITDA today — roughly 1.3 standard deviations below the 5-year mean of 20.5x… It is the cheapest the stock has been since 2013 outside of the 2008 panic." Quality Score 90/100 with Predictability 4.5★, Altman Z 3.44 (safe zone), Beneish M -2.49 (clean), ROIC 23.4%.
2. The margin trough has already reversed — Q1 FY26 printed a four-year high
The bear narrative is a structural margin problem. The data says the opposite: operating margin fell from 19.5% in 4Q24 to 13.2% in 4Q25 on inventory build and FX, then snapped back to 20.8% in 1Q26 — the highest in four years — with EPS of $0.66. Capex peaked in FY23-24 as Costa Rica / Puerto Rico capacity came online; FY25 FCF already rebounded to $434M from $288M.
Numbers — "1Q26 snapped back to 20.8% operating margin, the highest in four years"; Story — "Q1 FY2026 already showed 180 bps of non-GAAP operating margin expansion"; Numbers — "FCF rebounded to $434M in FY2025 and should keep rising as capex normalizes back toward 6–7% of revenue."
3. Activists + management pivot = forced capital return at the low
Browning West ($500M+ stake) and Jana Partners both filed in a single quarter. Management responded with a new chair (Dec 2025), a $50M/yr reorg, a $2B buyback authorization, a $2.2B three-year FCF commitment, and $290M of repurchases in FY25 — the first meaningful buyback in years, executed right at the low. Eight insiders including CEO White bought $2.52M of stock in the open market with zero sales.
People — "every open-market transaction by an insider was a BUY — eight insiders, 33,989 shares, $2.52M deployed with zero open-market sales"; Story — "a new board chair, a strategic review, an $89M reorganization charge, a $50M annual savings pledge, and an expanded $2B buyback authorization."
Bull price target: $102 (+57%) over 12–18 months — EV/EBITDA reversion to the 20-year mean of ~17.8x on FY26 EBITDA ~$1.15B, cross-checked against Fair Value of $102.70 and Medpsvalue estimate of $109.45. Primary catalyst: CooperSurgical strategic review outcome combined with one more CVI organic print above 5%.
Against
1. The growth engine is cut in half, not paused
CooperVision — 67% of revenue and essentially all the multiple — decelerated from 8% organic in FY24 to 5% in FY25 to 3% in Q1 FY26 on tough comps and FX help. This is the input that sets the whole multiple; at a 3–5% run-rate CVI is an Alcon-style compounder, not a premium-growth medtech.
Numbers — "CooperVision grew 5.2% in FY2025, decelerating from 7.7% in FY2024 — that single data point is most of the reason the stock is where it is"; Business — "Q1 FY26 came in at 3% organic on tough comps with currency help"; Story — initial FY25 organic guide cut from 8% to 4% in three consecutive prints.
2. Management was forced; the pivot is not strategy
Two activists landed in a single quarter (Browning West $500M+ Nov 2025; Jana Partners Oct 2025) and the board immediately yielded a seat, a strategic review, a new chair, an $89M reorg, and a buyback pivot. A company whose CSI segment was the "growth engine" in FY23 is now entertaining its divestiture at cycle-trough fertility multiples, while the prior M&A record (Cook Medical IVF terminated with a $45M break fee; Generate Life at $1.6B) is being quietly abandoned.
People — "Rosebrough was installed under a letter agreement with Browning West… a cooperation agreement, not a defeat, but a clear acknowledgement… that outside pressure was justified"; Story — "the acquisition-led growth model of 2021–2022 had not worked as advertised… the big acquisitions are not the integrated success stories they were sold as"; People — "Credibility Score: 5.5 / 10."
3. The $2.2B three-year FCF promise is arithmetic fiction
Management's new "contract with shareholders" requires ~$730M/yr of FCF from 2026–2028; FY25 actual was $434M, FY24 $288M, FY23 $215M. That is a 70% step-up from the most recent print, at the same time tariffs are eating 60–70bp of gross margin, CVI growth is halved, CSI fertility is at 1%, and capex still runs 9% of sales. Either the growth returns (contradicting point 1) or the cash target misses — and the whole re-rating case hangs on this number.
Numbers — "FCF rebounded to $434M in FY2025"; Story — "$2.2B three-year FCF target implies ~$730M/yr, well above FY2025's $434M — an ambitious ramp"; Business — "capex has run $300–420M annually, around 9% of sales, well above medtech peers at 3–5%"; Story — "China tariffs and mix as a 60–70bp gross margin headwind."
Bear downside target: $52 (-20%) over 12 months — FY26 non-GAAP EPS haircut to $4.30 × 12x multiple (cohort floor for mid-single-digit medtech compounders); EV/EBITDA 11x on ~$1.0B FY26 EBITDA cross-checks at ~$50. Primary trigger: a fourth consecutive CVI organic print under 5%, or a CSI sale at or below book value.
The Tensions
1. CVI organic growth: trough or new normal?
Bull says the CooperVision deceleration from 8% → 5% → 3% is a combination of tough FY24 comps, FX, China tariffs, and a reorg-induced P&L muddle — transitory, with MyDay and MiSight set to re-accelerate. Bear says the same sequence is structural — CooperVision is now a 3–5% compounder, and the guide being cut three times in a row is confirmation, not aberration. Both cite the same 8% / 5% / 3% walk. This resolves on two consecutive CVI organic prints above 5% — the first opportunity is Q2 FY26 (late May / early June 2026), the second is Q3 FY26 (late August 2026). Anything under 5% for a fourth straight quarter tips the tension to the Bear.
2. The activist pivot: unlock or capitulation?
Bull reads the Browning West stake, new chair, $2B buyback, $2.2B FCF target, and eight insider buys as the textbook setup where an activist forces a re-rating at the low. Bear reads the exact same sequence as a board capitulating under duress, abandoning the M&A growth model it defended two years ago, and entertaining a CooperSurgical divestiture at cycle-trough fertility multiples. Both cite the same events in Oct–Dec 2025. This resolves on the CooperSurgical strategic review outcome — a clean CSI separation at an accretive multiple with the buyback sustained is Bull's outcome; a CSI sale at or below book, or a "status quo" announcement that preserves the structure the activists targeted, is Bear's.
3. The $2.2B three-year FCF target: credible ramp or arithmetic fiction?
Bull says FY25's $434M of FCF already doubled FY23's $215M; capex peaked in FY23-24 and is normalizing toward 6–7% of sales, which alone gets most of the way to the $730M/yr pace. Bear says hitting $730M from $434M is a 70% step-up that collides with halved CVI growth, 60–70bp of tariff gross-margin drag, and capex still at 9% of sales. Both cite the same FY25 $434M starting point and the same $730M implied annual pace. This resolves on H1 FY26 FCF run-rate — the Q2 FY26 cash-flow statement (late May / early June) will show whether the business is tracking ~$350M or ~$200M through the first half. Under $300M at the half-way mark and the target becomes narrative, not arithmetic.
My View
Close call, slight lean cautious. The valuation is real — 13.8x on a 90-Quality business with a 23% ROIC, clean Beneish, and a 4.1-star predictability is genuinely rare, and the insider-buy cluster is the kind of signal that usually marks a low. But the first tension is doing most of the work: a stock multiple for a contact-lens oligopoly rests almost entirely on CVI organic growth, and three prints of a deceleration — culminating in a 3% handle last quarter — is not yet a trough; it is a line. I would wait for the Q2 FY26 print in late May / early June 2026 before stepping in, rather than pay for mean reversion that still depends on a number that is going the wrong way. The single condition that would flip this view: CooperVision organic growth prints above 5% in Q2 FY26 — on that one number the first tension collapses toward the Bull, the margin reset gets a revenue denominator behind it, and the 20-year-mean multiple argument goes from plausible to likely.